Steve has over 20 years of experience working in health technology assessment, evidence-based medicine, health economics, and pricing and market access within the pharmaceutical industry.
Prior to joining CRA, Steve was Senior Director for Global Health & Value at Pfizer responsible for global market access of hospital products in Pfizer’s established products business. His expertise has focused on pricing and market access in Europe, with in-depth experience of health technology assessment (HTA) in the UK. He has worked on a broad range of therapeutic areas throughout the lifecycle from Phase 2 to post loss of exclusivity.